Rossari Biotech's Q4 FY 2025-26 Quarterly Results

Result Summary

• Rossari Biotech Ltd reported a 20.9% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 21.1%.
• Its expenses for the quarter were up by 18.5% QoQ and 19.9% YoY.
• The net profit increased 40.3% QoQ and increased 33.5% YoY.
• The earnings per share (EPS) of Rossari Biotech Ltd stood at 8.29 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Rossari Biotech Ltd is a prominent player in the industry, primarily engaged in manufacturing specialty chemicals. The company's product portfolio is diverse, catering to several sectors including home and personal care, textile specialty chemicals, and animal health and nutrition. While specific recent developments are not provided, Rossari Biotech Ltd has been known for its innovation and commitment to sustainability, focusing on eco-friendly and technologically advanced solutions. The company's strategic initiatives often emphasize expanding its market reach and enhancing production capabilities to meet growing demands.

Revenue

The financial data for Rossari Biotech Ltd indicates a robust performance in terms of revenue generation for Q4FY26. Total income for this quarter amounted to ₹703.93 crores, showcasing a substantial quarter-over-quarter (QoQ) increase of 20.9% from ₹582.19 crores in Q3FY26. Additionally, there is a notable year-over-year (YoY) growth of 21.1% compared to ₹581.35 crores in Q4FY25. This consistent upward trajectory in revenue highlights the company's ability to effectively capture market opportunities and expand its sales base.

Profitability

Rossari Biotech Ltd's profitability metrics reflect a positive trend in Q4FY26. Profit Before Tax (PBT) rose to ₹63.73 crores, demonstrating a significant QoQ increase of 51.4% from ₹42.10 crores in the previous quarter. The YoY growth stands at 34.0%, up from ₹47.56 crores in Q4FY25. After accounting for tax expenses, the Profit After Tax (PAT) reached ₹45.97 crores, marking a 40.3% QoQ increase and a 33.5% YoY increase from ₹34.44 crores in Q4FY25. The Earnings Per Share (EPS) also experienced similar growth patterns, rising from ₹5.91 in Q3FY26 to ₹8.29 in Q4FY26, further confirming the company's enhanced profitability.

Operating Metrics

The operating metrics for Rossari Biotech Ltd reveal a pattern of growth in both income and expenses. Total expenses for Q4FY26 were reported at ₹640.20 crores, indicating an 18.5% increase from ₹540.08 crores in Q3FY26 and a 19.9% rise from the previous year's ₹533.79 crores in Q4FY25. The tax expenses also saw a notable increase, with an 87.9% QoQ rise and a 37.9% YoY increase. These increments in operating metrics suggest effective management of operational costs relative to revenue growth, aligning with the company's overall financial performance.